Cargando…

A preliminary study of the effect of curcumin on the expression of p53 protein in a human multiple myeloma cell line

Curcumin is an inexpensive, natural plant ingredient with protease inhibitor effects. The present study aimed to analyze the inhibitory effects of curcumin on the multiple myeloma (MM) RPMI 8226 cell line, and examine the underlying mechanism that promotes the apoptosis of RPMI 8226 cells. A growth...

Descripción completa

Detalles Bibliográficos
Autores principales:	LI, WEI, WANG, YAOMEI, SONG, YONGPING, XU, LINPING, ZHAO, JUNMEI, FANG, BAIJUN
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2015
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356419/ https://www.ncbi.nlm.nih.gov/pubmed/25789029 http://dx.doi.org/10.3892/ol.2015.2946

Ejemplares similares

Preliminary study on the relationship among stem cell markers, drug resistance and PI3K signaling pathway in multiple myeloma (MM) cell
por: Li, Ning, et al.
Publicado: (2020)

The Synchronous Presence of Multiple Myelomas and Other Primary Malignant Tumors: Case Series with Literature Review
por: Li, Ning, et al.
Publicado: (2020)

Expression of p53 protein isoforms predicts survival in patients with multiple myeloma
por: Rojas, Elizabeta A., et al.
Publicado: (2022)

Human leukocyte antigen-DRB1 gene polymorphism and aplastic anemia: A meta-analysis
por: Liang, Lijie, et al.
Publicado: (2023)

P01.15. Multiple Myeloma, chemotherapy and curcumin
por: Panutich, E, et al.
Publicado: (2012)

Coexistence of P190 and P210 BCR/ABL transcripts in chronic myeloid leukemia blast crisis resistant to imatinib
por: Junmei, Zhao, et al.
Publicado: (2015)

Apoptosis of mouse myeloma cells induced by curcumin via the Notch3-p53 signaling axis
por: Zhang, Ying, et al.
Publicado: (2019)

Targeting p53 by small molecule p53 activators in multiple myeloma
por: Saha, Manujendra N, et al.
Publicado: (2012)

miR‐17‐3p promotes the proliferation of multiple myeloma cells by downregulating P21 expression through LMLN inhibition
por: Xiang, Pu, et al.
Publicado: (2021)

Treatment of refractory/relapsed adult acute lymphoblastic leukemia with bortezomib-based chemotherapy
por: Zhao, Junmei, et al.
Publicado: (2015)

Assessment of TP53 lesions for p53 system functionality and drug resistance in multiple myeloma using an isogenic cell line model
por: Munawar, Umair, et al.
Publicado: (2019)

p53 Abnormalities and Potential Therapeutic Targeting in Multiple Myeloma
por: Teoh, P. J., et al.
Publicado: (2014)

Molecular Mechanisms of p53 Deregulation in Cancer: An Overview in Multiple Myeloma
por: Herrero, Ana B., et al.
Publicado: (2016)

Autologous hematopoietic stem cell infusion for sustained myelosuppression after BCMA–CAR-T therapy in patient with relapsed myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Use of Curcumin in Multiple Myeloma patients intolerant of steroid therapy
por: Ramakrishna, Rajeev, et al.
Publicado: (2020)

Safety and efficacy of CAR-T cell targeting BCMA in patients with multiple myeloma coinfected with chronic hepatitis B virus
por: Han, Lu, et al.
Publicado: (2020)

Curcumin stabilizes p53 by interaction with NAD(P)H:quinone oxidoreductase 1 in tumor-derived cell lines
por: Patiño-Morales, Carlos César, et al.
Publicado: (2019)

Curcumin-induced promoter hypermethylation of the mammalian target of rapamycin gene in multiple myeloma cells
por: Chen, Jiaqi, et al.
Publicado: (2019)

Sequence analysis of p53 response-elements suggests multiple binding modes of the p53 tetramer to DNA targets
por: Ma, Buyong, et al.
Publicado: (2007)

Expression pattern of the apoptosis-stimulating protein of p53 family in p53(+) human breast cancer cell lines
por: Wang, Changsong, et al.
Publicado: (2013)

Role of tumor suppressor p53 and micro-RNA interplay in multiple myeloma pathogenesis
por: Abdi, Jahangir, et al.
Publicado: (2017)

Clinical Significance of TP53 Abnormalities in Newly Diagnosed Multiple Myeloma
por: Ye, Fang, et al.
Publicado: (2021)

Deregulation and Targeting of TP53 Pathway in Multiple Myeloma
por: Jovanović, Katarina K., et al.
Publicado: (2019)

Loss of p53 enhances the tumor-initiating potential and drug resistance of clonogenic multiple myeloma cells
por: Chang, Yu-Tai, et al.
Publicado: (2023)

Recent updates on CAR T clinical trials for multiple myeloma
por: Lin, Quande, et al.
Publicado: (2019)

Expression of Neuron-Specific Enolase in Multiple Myeloma and Implications for Clinical Diagnosis and Treatment
por: Yang, Haiping, et al.
Publicado: (2014)

Curcumin Induces p53-Null Hepatoma Cell Line Hep3B Apoptosis through the AKT-PTEN-FOXO4 Pathway
por: Liou, An-Ting, et al.
Publicado: (2017)

P848: EXPRESSION PROFILE OF BCL-2 FAMILY PROTEINS IN MULTIPLE MYELOMA.
por: Sánchez, Cristina De Ramón, et al.
Publicado: (2023)

Front-line treatment of multiple myeloma
por: Cavo, Michele, et al.
Publicado: (2019)

Long-term stabilisation of myeloma with curcumin
por: Zaidi, Abbas, et al.
Publicado: (2017)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

P814: ANALYSIS OF TP53 ALTERATIONS BY WGS REVEALS BIALLELIC 17P DELETIONS IN MULTIPLE MYELOMA
por: Truger, Marietta, et al.
Publicado: (2023)

Prognosis, Biology, and Targeting of TP53 Dysregulation in Multiple Myeloma
por: Flynt, Erin, et al.
Publicado: (2020)

Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing
por: Li, Wei, et al.
Publicado: (2023)

Lysine120 Interactions with p53 Response Elements can Allosterically Direct p53 Organization
por: Pan, Yongping, et al.
Publicado: (2010)

Sensitizing human multiple myeloma cells to the proteasome inhibitor bortezomib by novel curcumin analogs
por: MUJTABA, TASKEEN, et al.
Publicado: (2012)

A Review of The Synergistic Effects of Curcumin with Proteasome Inhibitors in Multiple Myeloma Preclinical Models
por: Pandya, Shaunak K., et al.
Publicado: (2023)

Bortezomib combined with lenalidomide as the first-line treatment for the rare synchronous occurrence of multiple myeloma and pulmonary adenocarcinoma: A case report
por: Zuo, Wenli, et al.
Publicado: (2017)

miR-144-3p Suppresses Osteogenic Differentiation of BMSCs from Patients with Aplastic Anemia through Repression of TET2
por: Li, Ning, et al.
Publicado: (2019)

Clinical implications of cytogenetic heterogeneity in multiple myeloma patients with TP53 deletion
por: Hao, Suyang, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_vlpnkakkukg6vo6jp4tjknjai6